The leaders in Biotechnology and Molecular Biology 🧬 products in Jordan 🇯🇴 and Middle East since 2009.
In conclusion, the Chinese genetic industry is developing rapidly, with the help of loose government policies and more financial support, now is the time to break into the Chinese genetic market. For the start-up biotech companies, tailoring the product is crucial for the company to success. Fo...
Oxford Genetics, also known as OXGENE, specializes in the biotechnology sector with a focus on accelerating the development and manufacturing of cell and gene therapies. The company offers advanced technology and service solutions, including cell line engineering, scalable AAV production systems, and GMP...
Seattle Genetics Inc operates in the Biotechnology industry, a subset of the Health Care sector. The firm has a market capitalization of 3504.96 million, and 483 employees. Currently, 14 Wall Street Analysts cover the firm, including Alpha Street Research. Over the last 52 weeks the shares have...
Opus Genetics (NASDAQ:IRD) serves as a clinical-stage gene therapy company in the biotechnology sector to develop treatments for inherited retinal diseases. Use the CB Insights Platform to explore Opus Genetics's full profile.
Genetics Institute, the US biotechnology company, was part of the first wave of biotechnology start-ups in the 1980s. Although it was a leading company in the development of important therapeutics such as tissue plasminogen activator (t-PA) and erythropoietin (EPO), the Company was unable to ...
Company History: Genetics Institute, Inc., (GI) is a biotechnology firm engaged in the research, development, and commercialization of pharmaceuticals through recombinant DNA and other genetic technologies. The company has developed drugs to make the blood of hemophiliacs clot, as well as substances...
We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in ...
Mr. King has been employed in the life sciences industry for more than 25 years. From June 2008 to June 2010, he was the Chief Executive Officer of AverDx Incorporated, an international biotechnology company that develops novel biomarker diagnostics for critical diseases. From June 2002 to ...
for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX),Monogram Biosciences, Inc. (NASDAQ: MGRM)andin the leadership team ofVarian Medical Systems, Inc.(NASDAQ: VAR)involved in legal, business development and compliance matters, Kathy developed her passion for personalized ...